Featured Story

  • Nexvet regroups as key study on lead dog drug shows 'low probability' of success

    Nexvet Biopharma, which has been struggling to gain traction on Wall Street since its February IPO, said in a statement Wednesday that it is reassessing the study program for its lead compound, NV-01, after an initial review indicated that the current trial has a "low probability" of hitting the endpoint necessary for U.S. approval.

Lilly beats estimates on newly bulked-up animal health unit

Indianapolis-based Eli Lilly said Thursday that it earned 87 cents per share in the first quarter of 2015--10 cents more than analysts had expected--an achievement the company attributed largely to its $5.4 billion acquisition of Novartis Animal Health.

New study warns you can catch diseases from your pets

Researchers have discovered that health professionals are not adequately explaining the risk of pets passing diseases along to their owners. Now they're urging physicians and veterinarians to improve their efforts to communicate those risks to their clients--and offering tips to pet owners about how to minimize their chances of catching illnesses from their four-legged, finned or scaled friends.

Bayer closes MO animal health plant, citing excess capacity

After failing to sell its animal health production facility in St. Joseph, MO, Bayer HealthCare confirmed on Tuesday that it would close the site.

Dog data at AACR cancer confab may point to personalized treatments

At the annual meeting of the American Association for Cancer Research, researchers presented a gene expression model that veterinarians can use to predict how dogs with osteosarcoma will respond to the commonly used chemo drug doxorubicin, which could help both human and canine cancer patients.

FDA coordinates with pharma to address IV fluid shortage

The FDA's Center for Veterinary Medicine announced on April 13 that it has a plan in place to address a shortage of IV fluids used to treat large animals. The shortage of three-litre and five-litre doses has been caused by a combination of increased demand and decreased production, according to a statement from the FDA. 


From Our Sister Sites


Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.


Veracyte is selling $40 million of its common stock in a private placement to generate some cash for R&D, adding fuel to its engine as it inks new deals and looks to expand its portfolio.